Companies in #Site-Specific Bioconjugation

Firefly Bio is a clinical-stage bioconjugate and antibody-drug conjugate (ADC) company leveraging chemistry pioneered by Nobel laureate Carolyn Bertozzi to develop next-generation ADCs targeting KRAS-mutant and other solid tumors. Its lead programs combine site-specific bioconjugation with tumor-selective payload chemistries designed to widen the therapeutic index versus first-generation ADC platforms.